Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

Background: MIBC is an aggressive disease, with 5-year survival rates ranging from 36 to 48% for p T3/p T4/p N+tumors. Perioperative treatment can improve overall survival, with more robust evidence in favor of neoadjuvant chemotherapy. Few randomized studies have compared neoadjuvant and adjuvant t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Del Bene, Gabriella, Calabrò, Fabio, Giannarelli, Diana, Plimack, Elizabeth R., Harshman, Lauren C., Yu, Evan Y., Crabb, Simon J., Pal, Sumanta Kumar, Alva, Ajjai S., Powles, Thomas, De Giorgi, Ugo, Agarwal, Neeraj, Bamias, Aristotelis, Ladoire, Sylvain, Necchi, Andrea, Vaishampayan, Ulka N., Niegisch, Günter, Bellmunt, Joaquim, Baniel, Jack, Galsky, Matthew D., Sternberg, Cora N.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252384/
https://ncbi.nlm.nih.gov/pubmed/30510914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00463
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados